AntibioTx ApS

AntibioTx owns a novel platform to guide the development of new medicine to eliminate drug-resistant pathogens and reduce evolution of new resistance. The company was launched in 2011 and is funded by Novo A/S, The Advanced Technology Foundation, and private investors. The AntibioTx platform technology allows us to design and develop superior anti-infectives, cheap, efficiently, and at low risk by intelligently combining existing drugs to achieve novel synergies.